Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case.
Chagas disease is a zoonosis caused by the protozoan Trypanosoma cruzi. It presents as a chronic evolution and produces high morbidity and mortality in countries where the disease is endemic, as in ours. The skin disease is very rare and results from the reactivation of latent disease as a result of immunosuppression, presenting with acute, atypical, and severe lesions. We describe the case of a patient who was unaware of being a carrier of Chagas disease and presented reactivation after immunosuppressive therapy instituted to treat her systemic lupus erythematosus.
Department of Dermatology, Clínicas Hospital, Faculty of Medical Sciences, National University of Asuncion, Paraguay.
Lourdes Gonzalez
LG
Burgos
Beatriz Di Martino
BD
Ortiz
Andrés
A
Canese
Aldo
A
Ojeda
Marcia
M
Melo
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use*; D001706:Biopsy; D014355:Chagas Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009593:Nitroimidazoles / Q000627:therapeutic use; D012867:Skin / Q000469:parasitology / Q000473:pathology; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000627:therapeutic use; D014349:Trypanosoma cruzi / Q000302:isolation & purification
D007166:Immunosuppressive Agents; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D001379:Azathioprine; C009999:benzonidazole